March 8 (Reuters) – Drug developer Sarepta Therapeutics Inc said it had not received a rescheduled date for the review of its drug for a rare muscle wasting disorder by an FDA advisory panel and…
The post Sarepta says yet to receive new date for panel review of muscle wasting drug appeared first on NASDAQ.